US · Healthcare · Health Information Services
EPS came in at -0.04 against a street estimate of -0.05 — a beat of 20.0%.
Analysts rate Evolent Health Inc a buy (11 buy, 3 hold, 0 sell out of 14) with an average price target of $5.75.
| Fund | Stake |
|---|---|
| BlackRock Inc | 13.10% |
| Cadian Capital Management LP | 9.57% |
| Morgan Stanley - Brokerage Accounts | 7.93% |
| UBS Group AG | 5.52% |
| Rubicon Founders LLC | 5.14% |
| Engaged Capital LLC | 4.92% |
| D. E. Shaw & Co LP | 4.52% |
| Vanguard Capital Management, LLC | 4.23% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Evolent Health Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.